SynthesisFrontiers in endocrinology2026
Forearm vs sternocleidomastoid autotransplantation after total parathyroidectomy for secondary hyperparathyroidism: a network meta-analysis and global bibliometric study.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Secondary hyperparathyroidism (SHPT) is a common complication in chronic kidney disease (CKD), and parathyroidectomy (PTX) remains the definitive treatment for refractory cases. However, the optimal surgical strategy, particularly regarding the implantation site for autotransplantation, remains uncertain. Total parathyroidectomy with autotransplantation (TPTX + AT) is widely performed, but it is unclear whether forearm autotransplantation (TPTX + ATF) offers advantages over autotransplantation into the sternocleidomastoid muscle (TPTX + ATSCM). Methods: Using the Web of Science Core Collection (WOSCC), we performed a bibliometric analysis. We then systematically searched PubMed, Embase, the Cochrane Library, and major Chinese databases (CNKI, Wanfang Data, and VIP) from inception to 1 November 2025. We included randomized controlled trials and cohort studies comparing subtotal PTX (SPTX), TPTX, TPTX + ATF, and TPTX + ATSCM. The primary outcomes were SHPT recurrence and postoperative hypocalcemia. Bayesian network meta-analysis (NMA) was conducted to rank the treatments. Results: Twenty-seven studies involving 6979 patients were included, comprising 2493 patients treated with SPTX, 964 with TPTX, 3359 with TPTX + ATF, and 163 with TPTX + ATSCM. Compared to TPTX, both SPTX and TPTX + ATF showed higher risks of recurrence (OR 3.80, 95% CrI 1.67-10.78; OR 2.66, 95% CrI 1.04-8.33). No significant differences were observed between TPTX + ATF and TPTX + ATSCM with respect to recurrence (OR 0.66, 95% CrI 0.13-3.05) or postoperative hypocalcemia (OR 1.18, 95% CrI 0.18-6.23). Bibliometric analysis revealed global research activity from the United States and China, with stable contributions over the past two decades. Conclusion: Forearm and sternocleidomastoid autotransplantation showed no statistically significant differences in recurrence or postoperative hypocalcemia based on the available evidence.Current evidence does not support a definitive preference for either implantation site, although forearm implantation may remain a reasonable option in settings where graft monitoring and potential reintervention are important considerations. High-quality randomized trials are still needed to confirm these findings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251236587.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.